US2019000930A1PendingUtilityA1

Dietary supplements and formulations

Assignee: EASTERN VISION LTDPriority: Feb 13, 2015Filed: Sep 6, 2018Published: Jan 3, 2019
Est. expiryFeb 13, 2035(~8.5 yrs left)· nominal 20-yr term from priority
A61K 36/3482A61K 36/185A61K 36/577A61K 38/465A61K 31/197A61K 31/10A61K 45/06A61K 31/592A61K 31/4415A61K 31/355A61K 31/202A61K 38/54A61K 31/455A61K 31/519A61K 35/60A61K 31/7076A61K 36/53A61K 31/593A61K 31/525A61K 33/30A61K 38/168A61K 2300/00A61K 38/446A61K 31/4188A61K 36/068A61K 33/04A61K 31/714A61K 38/4873A61K 31/352A61K 31/14A61K 31/733A61K 31/685A61K 36/24A61K 31/19A61K 31/7048A61K 38/063A61K 36/41A61K 38/47A61K 31/145A61K 31/16A61K 33/42A61K 31/198A61K 31/59A61K 31/375A61K 31/12A61K 31/047A61K 33/34A61K 31/07C12Y 115/01001A61K 36/88A61K 31/122A61K 36/42A61K 33/24A61K 36/81A61K 31/185A61K 31/385A61K 31/205A61K 31/25A61K 33/06A61K 33/32
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are dietary supplements, formulations, kits and methods for administration to an individual with type II diabetes or at risk of developing type II diabetes. Provided herein are formulations, kits and methods useful for treating, preventing, supporting, controlling, restoring, and/or maintaining blood sugar levels in individuals with type II diabetes or at risk of developing the same. Also provided are formulations, kits and methods useful for reducing and/or eliminating requirement of ex-vivo insulin administration in an individual diagnosed with type II diabetes.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A dietary supplement in a form selected from the group consisting of a tablet, capsule, pill, emulsion, ointment, lotion, suppository, and aerosol, the dietary supplement consisting essentially of:
 at least one component selected from the group consisting of maca,  Cornus officinalis  fruit extract, and a combination thereof;   at least one component selected from the group consisting of berberine, bitter melon extract,  Gymnema sylvestre  leaf extract, banaba, carnitine, and combinations thereof;   at least one component selected from the group consisting of vitamin C,  Panax ginseng  root extract, Aswagandha root extract, holy basil leaf extract,  Rhodiola rosea  extract,  Eleutherococcus senticosus  extract, vitamin B5, cactus stem extract, phosphatidylserine, vitamin D, and combinations thereof;   at least one component selected from the group consisting of  Cordyceps sinesis  extract,  Gingko biloba  leaf extract, suma root,  Garcinia cambogia  extract,  Rehmannia glutinosa  extract,  Poria cocos  root extract, cinnamon extract, Fenugreek, Guggul, citrimax extract, salacia  oblonga  extract, vitamin E, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, magnesium, zinc, selenium, manganese, chromium, vanadium, zinc, calcium, alpha lipoic acid, N-acetyl-cysteine, 4-aminobenzoic acid (PABA), choline bitartrate, glutamine, glutathione, protein, fiber, inositol, phospholipids, milk thistle, luo han guo,  stevia  extract rebaudioside, superoxide dismutase, and combinations thereof; and   an excipient.   
     
     
         2 . The dietary supplement of  claim 1 , wherein the excipient is selected from the group consisting of gelatin, cellulose, medium-chain triglyceride (MCT) oil, silicon dioxide, stearic acid, and combinations thereof. 
     
     
         3 . The dietary supplement of  claim 1 , wherein the dietary supplement is used for supporting glucose level in a subject's blood. 
     
     
         4 . The dietary supplement of  claim 1 , wherein the dietary supplement is used for reducing the need for insulin administration. 
     
     
         5 . The dietary supplement of  claim 1 , wherein the dietary supplement supports, controls, restores, or maintains blood sugar levels in a subject. 
     
     
         6 . The dietary supplement of  claim 5 , wherein the subject suffers from symptoms or complications associated with diabetes. 
     
     
         7 . The dietary supplement of  claim 5 , wherein the subject suffers from symptoms associated with type II diabetes. 
     
     
         8 . The dietary supplement of  claim 5 , wherein the subject suffers from symptoms associated with type I diabetes. 
     
     
         9 . The dietary supplement of  claim 5 , wherein the subject has skin complications, eye complications, foot complications, heart diseases, or inflammation. 
     
     
         10 . The dietary supplement of  claim 5 , wherein the subject has neuropathy, diabetic ketoacidosis, kidney disease, hypertension, gastroparesis, or high cholesterol. 
     
     
         11 . The dietary supplement of  claim 5 , wherein the subject has pre-diabetes.

Join the waitlist — get patent alerts

Track US2019000930A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.